-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$22.00198.51% Upside
Acrivon Therapeutics, Inc. Common Stock Frequently Asked Questions
-
What analysts cover Acrivon Therapeutics, Inc. Common Stock?
Acrivon Therapeutics, Inc. Common Stock has been rated by research analysts at BMO Capital, Oppenheimer, H.C. Wainwright, Piper Sandler, JMP Securities, Jefferies in the past 90 days.